Iyuzeh™ (latanoprost) – New drug approval

- On December 14, 2022, Thea Pharma announced the FDA approval of Iyuzeh (latanoprost), for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Iyuzeh is the first preservative-free formulation of latanoprost. Other formulations of latanoprost are available under the brand name Xalatan® (generically available as well) and Xelpros®.
- In randomized, controlled clinical trials of patients with open angle glaucoma or ocular hypertension with mean baseline IOP of 19 to 24 mmHg, Iyuzeh lowered IOP by 3 to 8 mmHg vs. 4 to 8 mmHg by latanoprost ophthalmic solution preserved with benzalkonium chloride. Latanoprost ophthalmic solution preserved with benzalkonium chloride was approximately 1 mmHg more effective than Iyuzeh.
- Warnings and precautions for Iyuzeh include pigmentation, eyelash changes, intraocular inflammation, macular edema, herpetic keratitis, and contact lens use.
- The most common adverse reactions (5% to 35%) with Iyuzeh use were conjunctival hyperemia, eye irritation, eye pruritus, abnormal sensation in eye, foreign body sensation in eyes, vision blurred, and increased lacrimation.
- The recommended dosage of Iyuzeh is one drop in the affected eye(s) once daily in the evening.
- Thea Pharma plans to launch Iyuzeh in the second half of 2023. Iyuzeh will be available as a 0.005% ophthalmic solution.